

Independent Ethics Advisory Committee

The independent Ethics Advisory Committee (EAC) aims to meet every 6 months in the first 18 months, and then every 9 months thereafter. At the start of the project the EAC will agree on an ethical framework for evaluating the project. They will examine the findings of WP2 (Bioethics), consider data from the toxicology study and submit a report to the Commission on their findings. For the remainder of the project they will hold regular meetings (every 9-12 months) to provide input to WP4 (Ethical and Regulatory Approval of the Study) and to evaluate ethical issues relating to any adverse events during the Phase I/IIa safety/efficacy trial. The EAC had its first meeting in September 2013.

Chair: Jackie Leach Scully, Professor of Social Ethics & Bioethics, Policy, Ethics & Life Sciences Research Centre, Newcastle University, UK (with experience in molecular biology, neurobiology, bioethics specifically in relation to reproductive and genetic medicine, disability, and the social, feminist, and psychological aspects of moral processes)

Hilde Lindemann, Professor of Philosophy, Department of Philosophy, Michigan State University, US (with experience in feminist bioethics, feminist ethics, the ethics of families, and the social construction of persons and their identities)

Christoph Rehmann-Sutter, Professor of Philosophy and Ethics of Life Sciences, Institute of History of Medicine and Science Research, University of Lübeck, Germany (with experience in bioethics, philosophy, and sociology, and former Chair of the Swiss National Advisory Commission on Biomedical Ethics)

Sorcha Ui Chonnachtaigh, Lecturer in Ethics and Law, School of Law, Keele University, UK (with experience in philosophy, equality studies, and bioethics, specifically in relation to embryonic stem cell research)

Mark Sheehan, Oxford Biomedical Research Centre Ethics Fellow, Ethox Centre, Nuffield Department of Population Health, University of Oxford, UK (with experience in research ethics and governance, ethics of reproductive technologies, ethics of healthcare resource allocation, and methodology in applied ethics and bioethics)

Nick Watson, Professor (Institute of Health and Wellbeing) and Chair of Disability Studies (Sociology), School of Social and Political Sciences, Glasgow University, UK (with experience in disability in relation to disability theory, history, identity, and technology)

David Archard, Professor, School of Politics, International Studies and Philosophy, Queen's University Belfast, UK (with experience in moral and legal philosophy, applied ethics, specifically in relation to children, family and the state, and philosophy of public policy)

Simo Vehmas, Professor, Faculty of Social Sciences, University of Helsinki, Finland (with experience in philosophical issues in disability studies and special education)

Andrew Whitelaw, Emeritus Professor, Neonatal Neuroscience Group, School of Clinical Sciences, University of Bristol, UK (PI on several randomised trials of treatment for brain injury in newborn infants, also co-author of Nuffield Ethics Report on the Fetus and Neonate).